CDKN2B and neoplasm: We observed that CDKN2B-AS1, IGF2BP3, and hsa-miR-497-5p exhibited good prognostic abilities in subgroups such as Primary therapy outcome CR, Residual tumor R0, Post-Menopause, and Hormone therapy NO (Fig 6C).